Licensing status

Publication and contact information

Cardiovascular disease


MicroRNA-130 (miR-130);

Studies in human samples and mice suggest inhibiting miR-130- and miR-301-family miRNAs could help treat pulmonary hypertension (PH). In lung tissue samples from both mouse models of experimental PH and patients, expression of miRNAs in the miR-130 and miR-301 families was increased compared with that seen in samples from healthy mice or humans. In a mouse model of PH, intrapharyngeal injection of an anti-miR-130 miRNA decreased pathological pulmonary vascular proliferation and right ventricular remodeling compared with injection of control anti-miRNAs. Next steps include developing an antisense oligonucleotide inhibitor effective against the entire miR-130 and miR-301 miRNA families and formulating the compound as an inhaled therapeutic.

SciBX 7(29); doi:10.1038/scibx.2014.862
Published online July 31, 2014

Patent application filed; optioned to an undisclosed company

Bertero, T. et al. J. Clin. Invest.; published online June 24, 2014;
Contact: Stephen Y. Chan, Brigham and Women's Hospital, Boston, Mass.